Wengel Kathryn E sold $2.4M of JNJ
Wengel Kathryn E (EVP, Chief TO and Risk Officer) sold 10,000 shares of JOHNSON & JOHNSON (JNJ) at $241.15 ($2.41M total) on 2026-06-11.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale size, price, and post-transaction holdings of an EVP/CRO risk officer.
Market read
Provides incremental sentiment/flow information via insider selling, but lacks any accompanying fundamental catalyst.
What to watch
No 10b5-1 plan is indicated in the filing; traders may overinterpret this, but without additional context (e.g., multiple concurrent sales, size relative to holdings, or follow-on buys) it remains weak evidence.
Background
The article is a primary-source SEC Form 4 insider transaction disclosure for Johnson & Johnson.
Ticker impact
Johnson & Johnson disclosed an EVP sale: Wengel Kathryn E sold 10,000 shares on 2026-06-11 at $241.15 via an open-market transaction.
Low likelihood of a sustained price move; any impact is likely limited to short-term sentiment/flow optics.
This is a Form 4 open-market sale with no 10b5-1 plan stated; however, the filing is not accompanied by new company fundamentals, guidance, or regulatory/product developments.
Market effects
Minimal; single-insider transaction does not reset sector expectations for large-cap healthcare.
None indicated.
None indicated.
Counterpoint
The sale may be driven by diversification, taxes, or pre-existing compensation/portfolio management rather than a view on JNJ fundamentals.
Key entities
- issuerJohnson & Johnson
Subject of the SEC Form 4 insider transaction disclosure.
- insiderWengel Kathryn E
EVP, Chief TO and Risk Officer who sold 10,000 shares.
